



JONES LANG
LASALLE®

News Release

Contact: Joanne Bestall
E-mail: Joanne.bestall@am.jll.com
Phone: +1 312 228 2387

Jones Lang LaSalle Negotiates 40,000 SF Lease for KaloBios Pharmaceutical in South San Francisco

Jones Lang LaSalle's Project and Development Services is Project Manager of the 26,000 SF Retrofit

San Francisco, June 30, 2008 – Jones Lang LaSalle, the financial and professional services firm specializing in real estate, has negotiated a 40,000-square-foot lease at 260 East Grand Avenue in South San Francisco on behalf of KaloBios Pharmaceutical, a U.S. based, private monoclonal company. The facility will serve as its new headquarters and upon completion in July, there will be about 50 employees based at the new site.

Jones Lang LaSalle's Project and Development Services Group is serving as project manager for the 26,000-square-foot laboratory retrofit at the former chemistry building. The remaining 14,000 square feet of laboratory and office space is currently being marketed by Jones Lang LaSalle for sublease.

Managing Director of Jones Lang LaSalle, Steve Levere represented KaloBios and is leading the sublease efforts. Heather Horne, Senior Manager of Jones Lang LaSalle's Project and Development Services Group, is leading the build-out efforts.

The facility at 260 East Grand Avenue is located within the 600-acre Point Grand Business Park, one of the largest concentrations of life science buildings within the San Francisco Bay Area. The high-image office/lab building offers convenient access to Highway 101 and the San Francisco International Airport.

Jones Lang LaSalle's Project and Development Services group oversees and manages multi-site build-outs, renovations and new construction projects for clients on a worldwide basis. The group has more than 1,000 project managers across the country and 2,000 worldwide.

- more -

Jones Lang LaSalle Negotiates 40,000 SF Lease for KaloBios Pharmaceutical in San Francisco – Page 2

About KaloBios

KaloBios Pharmaceuticals, Inc., a U.S. based, private monoclonal company, uses its proprietary platform technology to develop first or best-in-class human antibody therapeutics. The company has multiple programs that are in seven Phase 1/2 clinical trials: KB001 is an anti-infective for *Pseudomonas aeruginosa* infections being tested in cystic fibrosis and in intensive care patients on a ventilator, and KB002 and KB003 are being evaluated in inflammatory conditions such as rheumatoid arthritis and asthma. The company's Humaneering™ technology offers advantages over other methods of human antibody creation in terms of immunogenicity, potency, and manufacturing yields. For more information, visit <http://www.kalobios.com>.

###

About Jones Lang LaSalle

Jones Lang LaSalle (NYSE: JLL) is a financial and professional services firm specializing in real estate. The firm offers integrated services delivered by expert teams worldwide to clients seeking increased value by owning, occupying or investing in real estate. With 2007 global revenues of \$2.7 billion, Jones Lang LaSalle has approximately 170 offices worldwide and operates in more than 700 cities in over 60 countries. The firm is an industry leader in property and corporate facility management services, with a portfolio of approximately 1.2 billion square feet worldwide. LaSalle Investment Management, the company's investment management business, is one of the world's largest and most diverse real estate with approximately \$50 billion of assets under management. For further information, please visit our Web site, www.joneslanglasalle.com.

200 East Randolph Drive Chicago Illinois 60601 | 22 Hanover Square London W1A 2BN | 9 Raffles Place #39-00 Republic Plaza Singapore 048619